Andrea De Censi, MD: What Does the Clinical Future Look Like for Low-Dose Tamoxifen in Noninvasive Breast Cancer?

Posted: Thursday, January 5, 2023

Andrea De Censi, MD, PhD, of Italy’s E.O. Ospedali Galliera, gives clinical context to his findings that low-dose tamoxifen (so-called babytam) given for 3 years still significantly prevents recurrences from noninvasive breast cancer after a median of 7 years from treatment cessation. Dr. De Censi discusses patient selection, the advantages of lower-dose tamoxifen, and the long-term outlook.